FMC (FMC) Stock Analysis & Forecast

Last earnings call, Jul 29, 2026 AI summary

What they said

FMC reported Q1 2026 results that exceeded the midpoint of guidance and outlined four operational priorities: ~$1B targeted debt reduction (including sale of India commercial business and licensing deals), improving competitiveness of the non-diamide core via manufacturing shifts to lower-cost Asia sites (target completion Q1 2027), managing the post-patent transition for Rynaxypyr, and supporting commercial growth of new active ingredients (Isoflex, fluindapyr, Dodhylex). Management expects H1 to represent an earnings trough with a significant sales and earnings ramp in H2 2026 (~$425M sales improvement vs H1 at midpoint) driven by non-diamide core (Brazil direct sales), Rynaxypyr (reduced partner headwinds and stronger branded mix), and new AIs (~$175M–$200M). CFO noted a 5% FX tailwind in Q1 but expects FX roughly neutral for the full year, higher interest expense (Q1 interest $64.8M; full-year 2026 guidance $255M–$275M), D&A guidance $160M–$170M, an adjusted effective tax rate of 16%–18%, and seasonal working capital build leading to higher net debt (net debt ~$4.1B; net debt/EBITDA ~5.2x). Management provided updates on registrations and licensing discussions and reiterated confidence in product pipeline (Isoflex and fluindapyr key growth drivers) while acknowledging uncertainties around input costs (geopolitical risks), tariffs recovery, and timing of certain registrations. Q&A demonstrated management confidence and detailed operational drivers, while also acknowledging risks related to macro inputs, generics, tariffs, and leverage.

Guidance

Full-year 2026: interest expense expected $255M–$275M; depreciation & amortization $160M–$170M; adjusted effective tax rate 16%–18%. FX expected to be roughly neutral for the full year (tailwind in H1, minor headwind H2). Management targeting ~$1 billion of debt paydown in 2026 (sale of India commercial business expected to sign in May, licensing upfront payments, noncore asset sales and real estate sale-leasebacks). Anticipated H2 sales improvement vs H1 at midpoint of about $425M driven by non-diamide core ($150M–$200M), Rynaxypyr ($50M–$80M) and new active ingredients ($175M–$200M). Company forecasts ~ $700M of Rynaxypyr sales in 2026 (approximately $600M branded, < $100M partner sales).

Risks flagged

Risks mentioned include: higher interest expense and elevated leverage (gross debt ~$4.5B; net debt ~$4.1B; net debt/EBITDA ~5.2x), FX volatility, uncertainty in timing and proceeds from asset sales (India sale, other noncore assets), macro and geopolitical risks affecting input costs and transportation (Iran conflict impacts), tariff recovery uncertainty and legal/process timing for refunds, continued pressure from low-cost generics on core portfolio, and timing risk on product registrations (which affect new AI growth).